In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $1.50. The company’s shares closed yesterday at $0.47.
According to TipRanks, McCarthy is an analyst with an average return of -28.4% and a 20.49% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Lineage Therap, and Plus Therapeutics.
Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $2.25, which is a 377.81% upside from current levels. In a report released on May 10, BTIG also assigned a Buy rating to the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
MTNB market cap is currently $102.3M and has a P/E ratio of -4.97.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
Read More on MTNB:
- Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
- Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
- MTNB Upcoming Earnings Report: What to Expect?
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
- Matinas BioPharma announces presentation on MAT2203 at EECMID
